PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Diderot—Paris 7
InventorsNicolas Charles, Christophe Pellefigues
Life of this patent
Estimating the term…
Abstract
A PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, are provided to patients in need thereof to prevent or treat disease including systemic lupus erythematosus (SLE).
Claims7
A method for treating SLE in a patient in need thereof, wherein said method comprises administering to said patient laropiprant in combination with CAY10471 (TM30089).
A method for treating SLE in a patient in need thereof, wherein said method comprises administering to said patient a pharmaceutical composition comprising laropiprant and CAY10471 (TM30089).
Dependencies are inferred from the claim text.